

RESOLUTION

Subject: Transfer of Cannabis to Schedule III Controlled Substance

Submitted by: Donnie Stacy, MD

Referred to: Reference Committee

WHEREAS, on May 21, 2024 the Department of Justice proposed to transfer cannabis from schedule I of the Controlled Substances Act (CSA) to schedule III of the CSA, consistent with the view of the Department of Health and Human Services (HHS) that cannabis has a currently accepted medical use (CAMU) and a potential of abuse less than the drugs or other substances in schedules I and II (Schedules of Controlled Substances: Rescheduling of Marijuana 21 CFR Part 1308 [Docket No. DEA-1362; A.G. Order No. 5931-2024]); and

WHEREAS, the Kentucky Medical Association (KMA) advocates for further clinical research of cannabis in the treatment of medical conditions (Res 2015-16, 2015 HOD); and

WHEREAS, the rescheduling of cannabis to schedule III would allow for more extensive clinical research and pharmaceutical companies could submit Investigational New Drug Applications (INDs) and New Drug Applications (NDAs) for cannabis-based products to demonstrate their safety, efficacy, and manufacturing quality (<https://www.mwe.com/insights/doj-proposes-to-reschedule-marijuana-cannabis-to-schedule-iii/>); now, therefore, be it

RESOLVED, that KMA supports the transfer of cannabis from schedule I of the Controlled Substances Act (CSA) to schedule III.